Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97822923

Filing Date: 03/03/2023

To the Commissioner for Trademarks:

MARK: GENGLYCOS (Standard Characters, see mark)
The literal element of the mark consists of GENGLYCOS. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Ultragenyx Pharmaceutical Inc., a corporation of Delaware, having an address of
      60 Leveroni Court
      Novato, California 94949
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations and substances for the treatment of metabolic and rare diseases and disorders; gene therapy products for the treatment of metabolic and rare diseases and disorders
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, metabolic, and rare diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; compiling and sharing of patient data for research purposes in the field of metabolic and rare diseases and disorders; medical and scientific research information in the field of metabolic and rare diseases and disorders
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 044:  Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of metabolic and rare diseases and disorders
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Anne H. Peck. Other appointed attorneys are Kayla Blaker, Susan Piascik Christoff, Juliana Finley, Brian Focarino, Bobby A. Ghajar, Colette A. Ghazarian, Rebecca Givner-Forbes, Kelley B. Harrington, Shannan Higgins, Ariana G. Hiscott, Brendan J. Hughes, Judd D. Lauter, Asheton Lemay, Ari Lipsitz, John Paul Oleksiuk, Elizabeth F. Reinhardt, Elisa Rosen, Jane van Benten, Colleen Wellington-Caban and Jessica M. Williams. Anne H. Peck of Cooley LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      Suite 700
      1299 Pennsylvania Ave NW
      Washington, District of Columbia 20004
      United States
      trademarks@cooley.com
The docket/reference number is 315613-20000.
Anne H. Peck submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Anne H. Peck

PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): peckah@cooley.com; bfocarino@cooley.com; myoung@cooley.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $1050 has been submitted with the application, representing payment for 3 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Paul Wickman/   Date: 03/03/2023
Signatory's Name: Paul Wickman
Signatory's Position: Senior Vice President, Intellectual Property
Signatory's Phone Number: 000-000-0000
Signature method: Sent to third party for signature
Payment Sale Number: 97822923
Payment Accounting Date: 03/03/2023

Serial Number: 97822923
Internet Transmission Date: Fri Mar 03 21:31:52 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XX-2023030321315318
9409-97822923-8607b24348e38937acc6e4966e
2e58e99e308db1c9a54e158628f8693a65562a4-
DA-31529501-20230302212137298278